Drug Trial Extension By FDA Doesn't Change Baird's Outlook On Sarepta
June 27, 2016 at 16:01 PM EDT
Last week, Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Phase 3 ESSENCE study was updated and extended from 48 to 96 weeks. To many, the ...